Carregant...
Miniatura

Tipus de document

Altres

Versió

Versió publicada

Data de publicació

Llicència de publicació

cc-by-nc (c) Escudero-Saiz, Victor J. et al., 2025
Si us plau utilitzeu sempre aquest identificador per citar o enllaçar aquest document: https://hdl.handle.net/2445/226469

Extracorporeal photopheresis for refractory BK virus-associated nephropathy in kidney transplantation

Títol de la revista

Director/Tutor

ISSN de la revista

Títol del volum

Resum

Background BK virus-associated nephropathy (BKVAN) remains an important risk factor for kidney graft loss. The current strategy to treat the BKVAN consists in reducing immunosuppressants. However, this strategy increases the risk of graft rejection, especially in highly sensitized patients or those with previous rejection episodes. Extracorporeal photopheresis (ECP) has been used for the treatment of T cell-mediated disorders, such as solid organ rejection in cardiac, lung and hepatic transplantation, due to its immunotolerogenic effect. In addition, some data suggest that ECP might also have an immunogenic effect, generating an immune response against infections. Methods Herein we present a single-center case series of 13 patients with refractory histological-diagnosed BKVAN, where ECP was used after the failure of standard therapy. The cohort had a median age of 51 years (interquartile range 42-59), with 46% considered low immunological risk (cPRA 0%) and 54% high risk (cPRA >50%). ECP was initiated a median of 21.3 weeks (5.9-49.1) after BKVAN diagnosis, with patients receiving a median of 11 sessions (10-20). Results After starting ECP, serum BK viral load significantly decreased by 55.3%, 95.9%, 99.7% and 99.9% at 3, 6, 12 and 18 months after ECP, respectively, while kidney function slowly decreased but at a lower rate than the historical group not treated with ECP, and no adverse events were observed. Despite the reduction in immunosuppression, only one patient experienced graft rejection during follow-up, with no major impact on graft function. These findings indicate that ECP may provide potential therapeutic benefits for BKVAN and could warrant further investigation in the context of kidney transplantation.

Citació

Citació

ESCUDERO-SAIZ, Victor j., XIPELL FONT, Marc, GONZALEZ ROJAS, Ángela, RODRIGUEZ ESPINOZA, Diana maría, CACHO, Judit, ARANA ALIAGA, Carolt, PIÑEIRO, Gastón julio, VENTURA ABREU AGUIARÀ, Pedro, ROVIRA JUÁREZ, Jordi, LARQUE, Ana b., CHARRY, Paola, CID VIDAL, Joan, OPPENHEIMER, Federico, BODRO, Marta, LOZANO MOLERO, Miguel, DIEKMANN, Fritz. Extracorporeal photopheresis for refractory BK virus-associated nephropathy in kidney transplantation. _Clinical Kidney Journal_. 2025. Vol. 18, núm. 12, pàgs. sfaf250. [consulta: 7 de febrer de 2026]. ISSN: 2048-8513. [Disponible a: https://hdl.handle.net/2445/226469]

Exportar metadades

JSON - METS

Compartir registre